Blood And Blood Components - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The blood and blood components market size is expected to grow from USD 16.30 billion in 2025 to USD 17.20 billion in 2026 and is forecast to reach USD 22.20 billion by 2031 at 5.29% CAGR over 2026-2031. This report is Segmented by Component (Red Blood Cells, Platelets, Plasma, Cryoprecipitate), Collection Method (Apheresis, Whole-Blood-Derived), Application (Trauma & Surgery, Cancer Treatment, Anemia Management, Obstetrics), End User (Hospitals, Blood Centers, Ascs), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Market Forecasts are Provided in Terms of Value (USD).

Global Blood And Blood Components Market Trends and Insights

Rising Surgical Volumes in Complex Specialties

Outpatient procedures in the United States are expected to climb 21% during 2025 to 2035, illustrating the shift toward ambulatory care. Complex oncologic resections and robotic-assisted orthopedic cases still mandate cross-matched red cells and platelets on standby, sustaining hospital inventories. Satellite blood depots are proliferating near large ambulatory surgical centers, yet decentralized stock elevates cold-chain overheads and demands real-time visibility. FDA Current Good Tissue Practice and AABB standards oblige these centers to document transfusion protocols, adding compliance costs that only large systems can easily absorb.

Oncology-Induced Anemia and Thrombocytopenia Support

CAR-T and high-dose chemotherapy produce severe cytopenias in 10-25% of treatment cycles, triggering prophylactic platelet transfusions below 10,000/μL as guided by ASCO and ASH. Hospitals are adopting pathogen-reduction platforms such as INTERCEPT, cleared by the FDA in 2025, to extend shelf life and curb bacterial contamination. As survival improves, each patient requires more transfusions over a longer horizon, reinforcing steady growth for the blood and blood components market.

Patient Blood Management Reducing Allogeneic Transfusions

PBM bundles preoperative anemia correction, intraoperative cell salvage, and restrictive thresholds have cut red-cell use by up to 60% and reduced mortality odds to 0.33 in German multicenter studies. Joint Commission standards now oblige hospitals to audit transfusion appropriateness, compressing demand even as surgical complexity climbs.

Other drivers and restraints analyzed in the detailed report include:

• Trauma and Road-Injury Burden Elevating Emergency Transfusions
• Aging Populations Increasing Perioperative Transfusion Intensity
• Shrinking Donor Pools and Seasonal Shortages

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Red blood cells generated 65.18% of 2025 revenue, yet platelets are on track for a 6.50% CAGR to 2031 as CAR-T and intensified chemotherapy expand thrombocytopenia cases. Plasma and cryoprecipitate continue to support coagulation-factor replacement in massive transfusion protocols, but pathogen-reduction systems are shifting the mix toward higher-margin, longer-shelf-life platelet products. INTERCEPT’s 2025 FDA authorization is emblematic of technology’s role in this shift.

Whole-blood-derived platelets remain critical across regions with limited apheresis capacity, yet stringent bacterial-contamination rules now add USD 50-100 to per-unit costs, nudging hospitals toward safer, pretreated supplies. Plasma fractionation investments, EUR 160 million by Grifols in Barcelona, underline a tilt toward derivatives with stronger margins.

Whole-blood collections captured 72.18% of 2025 revenue thanks to entrenched mobile drives, but apheresis is heading for a 6.92% CAGR through 2031. Fresenius Kabi’s Aurora Xi software, cleared in 2025, raised plasma yield by 88 mL per donation, illustrating the incremental productivity that sustains apheresis growth.

Mobile collection remains indispensable for rural outreach, yet suppliers are exiting low-margin businesses. Haemonetics sold its whole-blood assets to GVS for USD 67.1 million in 2025 to focus on plasma and platelet automation. China’s updated 2024 guidelines similarly prioritize automated, pathogen-reduced collections, securing momentum for apheresis in Asia-Pacific.

Complete Report Scope:

• By Component
  • Red Blood Cells (RBCs)
  • Platelets (Apheresis-derived, Whole-blood-derived)
  • Plasma (FFP/FP24)
  • Cryoprecipitate/Cryo Reduced Plasma
• By Collection Method
  • Apheresis Collections
  • Whole-blood-derived Components
• By Application
  • Trauma & Surgery
  • Cancer Treatment / Hemato-oncology Support
  • Anemia and Chronic Disease Management
  • Obstetrics & Gynecology / Postpartum Hemorrhage
• By End User
  • Hospitals
  • Standalone/Regional Blood Centers
  • Ambulatory Surgical Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America contributed 36.19% of global revenue in 2025, maintaining the largest blood and blood components market share. The U.S. FDA guidance in 2023 that permits 14-day cold storage of platelets lets trauma centers place inventory closer to remote highways and emergency medical services. This regulatory flexibility reduces wastage from expired units and supports steady growth even as Patient Blood Management programs restrain red-cell demand in urban hospitals. Persistent donor shortages remain a structural challenge, highlighted by the American Red Cross declaration of a national shortage in January 2024.

Asia-Pacific is forecast to log a 6.81% CAGR through 2031, the fastest among all regions within the blood and blood components market. China’s hospital capacity boost, coupled with a USD 2.4 billion CAR-T segment that is expanding at 28.9% annually, lifts platelet demand and accelerates adoption of apheresis automation. Japan’s aging population, where citizens over 65 already exceed 29%, forces the Japanese Red Cross to run targeted youth campaigns and pilot extended eligibility criteria to stabilize donations. Regional regulators are still evaluating pathogen-reduction and genotyping protocols pioneered in the West, creating a patchwork of standards that suppliers must navigate to unlock the full Asia-Pacific opportunity

Europe shows steady but slower expansion as national blood services roll out large-scale genotyping that cut alloimmunization in sickle-cell cohorts by up to 90%. Even so, summer vacations and year-end holidays still depress donor turnout by 15-20%, prompting elective-surgery cancellations and inter-country unit transfers within the European Union. Middle East and Africa as well as South America face higher trauma burdens and fragmented collection networks, driving hospitals to prioritize O-negative stocks and adopt cold-stored platelet protocols endorsed by the WHO.

List of Companies Covered in this Report:

• Asahi Kasei Medical
• B. Braun
• Baxter
• Bio Products Laboratory (BPL)
• CSL Behring
• Fresenius
• Grifols
• Haemonetics
• JMS Co., Ltd.
• Kaneka
• Kawasumi Laboratories
• Kedrion Biopharma
• MacoPharma
• Nikkiso Co., Ltd.
• Nipro
• Octapharma
• PuriBlood Medical
• Takeda Pharmaceuticals
• Terumo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support